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Abstract
Background: UCP2 (uncoupling protein 2) plays an important role in cardiovascular diseases and recent studies
have suggested that the A55V polymorphism can cause UCP2 dysfunction. The main aim was to investigate the
association of A55V polymorphism with cardiovascular events in a group of 611 patients enrolled in the Medical,
Angioplasty or Surgery Study II (MASS II), a randomized trial comparing treatments for patients with coronary artery
disease and preserved left ventricular function.
Methods: The participants of the MASS II were genotyped for the A55V polymorphism using allele-specific PCR
assay. Survival curves were calculated with the Kaplan–Meier method and evaluated with the log-rank statistic. The
relationship between baseline variables and the composite end-point of cardiac death, acute myocardial infarction
(AMI), refractory angina requiring revascularization and cerebrovascular accident were assessed using a Cox
proportional hazards survival model.
Results: There were no significant differences for baseline variables according genotypes. After 2 years of follow-up,
dysglycemic patients harboring the VV genotype had higher occurrence of AMI (p=0.026), Death+AMI (p=0.033),
new revascularization intervention (p=0.009) and combined events (p=0.037) as compared with patients carrying
other genotypes. This association was not evident in normoglycemic patients.
Conclusions: These findings support the hypothesis that A55V polymorphism is associated with UCP2 functional
alterations that increase the risk of cardiovascular events in patients with previous coronary artery disease and
dysglycemia.
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Background
Cardiovascular diseases are the leading causes of death
among adults [1]. Many risk factors such as age, gender,
lipid abnormalities, hypertension, smoking, and genetic
factors influence the occurrence and progress of the dif-
ferent atherosclerotic processes and diabetes. Indeed,
70% of patients with acute myocardial infarction (AMI)
have either diabetes or impaired glucose tolerance [2].
Reactive oxygen species (ROS) and inflammatory cells,
particularly monocytes and macrophages, have a major
role in the pathogenesis of atherosclerosis [1]. ROS are
also associated with the pathogenesis of atherosclerotic
macrovascular disease in diabetic patients. At least four
molecular mechanisms have been implicated in glucose-
mediated vascular damage (advanced glycation end-
products, AGE, Protein kinase C, polyol and hexosamine
pathway). All of them seem to be related to overpro-
duction of superoxide by the mitochondrial electron-
transport chain, as a response to hyperglycemia [3].
In this context, UCP2 (uncoupling protein 2), a physio-
logical down-regulator of ROS, might play an important
role in cardiovascular diseases. Several studies have
already described that UCP2 has an anti-atherogenic effect
in the vascular wall [4], improves tolerance to cardiac
ischemia [5,6] and protects cardiomyocytes from oxidative
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stress-induced cell death [7]. This role of UCP2 was
demonstrated in transplanted mice (UCP2 -/-), which
have presented larger atherosclerotic lesions, increased
nitrotyrosine staining, suggesting enhanced oxidative
stress, and a significant increase in macrophage accumula-
tion in vascular lesions [8].
Nowadays, the exact functions of UCP proteins are
not fully established and may be different according to
assayed specific tissue. In β cells, UCP2 over expression
leads to decreased insulin secretion. Thus, UCP2 distur-
bances can be related to the causes and complications of
type 2 diabetes mellitus, both related to increased ROS
production.
The A55V polymorphism has been associated with
energy metabolism misbalance [9], higher risk of type 2
diabetes, lower HDL, high atherogenic index [10] and
lower levels of leptin [11]. Besides, other studies have
already associated VV genotype to lower degree of
uncoupling, more efficient energy utilization, lower fat
oxidation and increased ROS production suggesting that
A55V cause UCP2 dysfunction [12,13].
In this scenario, the main aim of this study was to
investigate whether the A55V polymorphism is associa-
ted to cardiovascular events in a group of 611 patients
enrolled in the MASS II [14,15], a study that compared
therapeutic strategies for individuals with multi-vessel
coronary artery disease (CAD).
Methods
Patient selection
Studied patients were selected from the prospective,
randomized and controlled Medicine, Angioplasty, or
are medical treatment, angioplasty or stent (percutaneous
coronary intervention, PCI), and myocardial revasculariza-
tion (coronary artery bypass grafting, CABG) in patients
with multi-vessel stable CAD with preserved left ventricu-
lar function [14,15].
Methodological details were described by Hueb et al.
Briefly, patients with angiographically documented
proximal multivessel coronary stenosis of more than
70% by visual assessment and documented ischemia
were considered for inclusion. Ischemia was documented
by either stress testing or the typical stable angina as-
sessment of the Canadian Cardiovascular Society (CCS)
(class II or III). Patients were enrolled and randomized if
there was agreement on the part of the surgeon and
interventionist that revascularization could be attained
by either strategy. Exclusion criteria included unstable
angina or acute MI requiring emergency revasculariza-
tion, ventricular aneurysm requiring surgical repair, left
ventricular ejection fraction of <40%, a history of PCI or
CABG, and single-vessel disease. Patients were also
excluded: if they had a history of congenital heart
disease, valvular heart disease, or cardiomyopathy; if they
were unable to understand or cooperate with the proto-
col requirements or to return for follow-up; or if they
had left main coronary artery stenosis of 50% or more,
or suspected or known pregnancy or another coexisting
condition that was a contraindication to CABG or PCI.
Patients were then randomized to continue with aggres-
sive medical therapy (MT) alone or to undergo PCI or
CABG concurrently with MT [14,15].
Two thousand seventy-six candidates who had indica-
tions for myocardial revascularization were evaluated
from May 1995 to May 2000. Of these, 611 patients were
eligible and met all inclusion criteria to be randomly
assigned to 1 of the 3 therapeutic groups: medical treat-
ment (n = 203), PCI (n = 205), and CABG (n = 203).
The primary end-point of this study was to compare the
frequencies of major cardiac events, such as acute MI,
overall mortality or refractory angina requiring revascu-
larization procedures and stroke. The main conclusion
of the MASSII was relatively low rates of death with all
3 treatment regimens during the first and second follow-
up years.
All subjects gave informed consent, and the Ethics
Committee of the Heart Institute of the University of
Sao Paulo - Brazil approved the study.
Data collection
The beginning of treatment was considered to be the ran-
domized date and patients were studied by the intention
to treat principle. The follow-up time for all patients in
this study was 5 years with clinical visits conducted in a
6-month interval. The collected demographic and labora-
tory data included age, gender, angiographic findings and
traditional risk factors, such as history of previous coro-
nary events, hypertension, diabetes, BMI (body mass
index), severity of angina, smoking status, and cholesterol
and triglycerides profile. Blood samples were obtained
from each participant at randomization.
Symptoms of angina were graded according to their
severity and were considered refractory only when pa-
tients had been treated with full anti-ischemic therapies.
Myocardial infarction was defined as the presence of sig-
nificant new Q waves in at least 2 ECG leads or symp-
toms compatible to MI associated with creatinine
kinase-MB elevations. Cardiac mortality was defined
when patient died of MI.
Glycemic status was defined using effective WHO
classifications at that time of the randomization. Briefly,
diabetic patients should present classic symptoms of
hyperglycemia and an abnormal blood test [plasma
glucose concentration ≥7 mmol/L (or 126 mg/dL) or
≥11.1 mmol/L (or 200 mg/dL) 2 hours after a 75 g glu-
cose drink]. Impaired glucose tolerance were diagnosed
in patients with fasting plasma glucose <7.0 mmol/L
(or 126 mg/dL) and 2 hour post 75 g glucose drink of
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≥ 7.8 mmol/L or 140 mg/dL and <11.1 mmol/L
(or 200 mg/dL). Patients with diabetes and impaired
glucose tolerance composed the dysglycemic group.
A55V genotyping
Genomic DNA was extracted from leukocytes in sam-
ples of whole blood following standard techniques [16].
Genotyping was performed with an Array Tape techno-
logy (Douglas Scientific, Alexandria MN). A modified
allele-specific PCR assay as described by Myakishev
et al. was used [17]. Briefly, PCR were performed with
50 ng of genomic DNA in a total volume of 10 μlL con-
taining 5 pmol of each primer, 100 μmol dNTPs, 0.3 U
Taq DNA polymerase (Lab Trade, Brazil). An average
genotyping success rate of more than 95% was obtained
and, as quality control, an average genotyping accuracy
of more than 98% was observed by re-genotyping of 32
samples.
Statistical analysis
Categorical variables were presented as percentage
while continuous variables were presented as mean ±
standard deviation. General characteristics, biochemical
and cardiovascular event frequencies were analyzed
using Student’s t test for continuous variables and the
Chi-square test or Fisher’s test for categorical variables.
Survival curves were constructed with the Kaplan–Meier
method and differences between the curves were evaluated
with the log-rank statistic. We assessed the relationship
between baseline variables and composite end-point
events using a Cox proportional hazards survival model.
Hazard ratios (relative risks) with 95% confidence intervals
Table 1 Baseline clinical characteristics
AA+AV (n= 383) VV (n= 176)
Mean±SD Mean±SD p
Frequency (%) 68.5 31.5
Gender (man, %) 67.6 69.3 0.690
Age (y) 59.2±9.3 60.5±8.8 0.581
Hypertension (%) 56.7 62.5 0.193
Diabetes (%) 26.9 25.7 0.951
Glucose intolerance (%) 20.0 20.0
0.790Normal Glucose Tolerance (%) 53.1 54.3
Dysglicemic (%) 46.9 45.7
High triglycerides (%) 55.8 58.6 0.537
LogTG* 2.2±0.2 2.2±0.2 0.308
Total Cholesterol (mg/dL) 222.0±48.3 224.8±47.2 0.522
LDL (mg/dL) 146.9±43.2 147.7±44.8 0.837
HDL (mg/dL) 37.4±10.5 37.4±10.6 0.961
Metabolic Sd (%) 51.2 47.3 0.462
Total Metabolic Sd 2.6±1.1 2.7±1.1 0.498
Obesity (%) 20.9 21.7 0.841
Double-vessel (%) 40.5 42.6
0.632
Multi-vessel (%) 59.5 57.4
Medical therapy (%) 32.4 33.0
0.935PCI (%) 33.9 32.4
CABG (%) 33.7 34.7
Angina CCS 1 (%) 6.1 6.8
0.475Angina CCS 2 (%) 64.0 58.2
Angina CCS 3 + 4 (%) 29.8 34.9
Current smoker (%) 31.6 29.0 0.534
AMI (inicial exams) (%) 45.4 44.9 0.904
* Tryglicerides values were log transformed before comparison.
PCI: percutaneous coronary intervention.
CABG: coronary artery bypass surgery.
CCS: Canadian Cardiovascular Society.
AMI: acute myocardial infarction.
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(CI) demonstrate the risk for combined events. Multiple
testing correction was not performed. A value of p≤0.05
was considered significant for comparisons. Statistical
analyses were performed with SPSS 13.0 for Windows.
The Hardy-Weinberg equilibrium was conducted with
Haploview 4.0.
Results
The genotypic distribution for the A55V polymorphism
was 20.7% of AA (n=116), 47.8% of AV (n=267) and 31.5%
of VV (n= 176). Genotypic distributions were in accordance
with the predicted by the Hardy-Weinberg equilibrium.
The Ala/Ala (AA) and the Ala/Val (AV) genotypes
were combined and compared with the Val/Val (VV)
genotype group. There was no significant difference in
baseline values between these groups (Table 1).
From 611 eligible patients, 559 individuals were geno-
typed and followed-up. There were 260 dysglycemic
patients (148 diabetic and 112 glucose intolerants) and 299
patients with normal glucose tolerance as shown in Table 1.
There were no differences between normoglycemic and
dysglycemic patients regarding to cardiovascular events
incidence during the first two follow-up years (Table 2).
Stratifying our analysis by glucose homeostasis, signifi-
cant differences were found in the subgroup of patients
with dysglycemia after two years of follow-up. Patients
carrying the VV genotype had a higher incidence of AMI
(p=0.026), death+AMI (p=0.033), necessity of a new
revascularization intervention (p=0.009) and combined
events (p=0.037) (Table 2). Curiously, differences accor-
ding to genotypic groups after 5 years of follow-up were
not observed in dysglycemic, except for the variable
AMI (p=0.025). For the normoglycemic patient group,
no significant difference was found according to geno-
types (Table 2).
Similar results were found when Kaplan-Meier sur-
vival curves were constructed. There were significant
differences for the incidence of AMI, new revasculariza-
tion procedures and combined events as shown in
Figure 1. Finally, modeling end-point events using a Cox
proportional hazards model adjusted for age, sex, ran-
domized treatment, and BMI, a significant interaction
between dysglycemia and UCP2 genotype was observed
for combined end-points (p = 0.03), incident myocardial
infarction (p = 0.009), and new revascularization proce-
dure (p = 023).
Discussion
We investigated the relationship between the A55V poly-
morphism and the incidence of cardiovascular events in
patients with CAD. Our main findings showed that A55V
is associated to increased risk of cardiovascular events in
patients with previous CAD and dysglycemia after two
years of follow-up.
Other studies have already suggested that A55V poly-
morphism cause UCP2 dysfunction [12,13] supporting
our findings. However, functional studies are necessary
to confirm these affirmations and explain the association
of VV genotype and cardiovascular events observed only
in disglycemic patients. In this way, the CARDIA study
reported the presence of diabetes in 5.8% of participants
homozygous for the V allele which was statistically greater
than the 3.3% and 3.7% in the AA and AV genotypes,
respectively [13]. These results extend the findings from
studies of Ala55Val or other UCP2 polymorphisms
involved in the development of type 2 diabetes mellitus
[18,19].
Table 2 Cardiovascular event incidences in the entire
cohort of patients, in the dysglycemic patients and in the
normoglycemic patients
Entire cohort of patients
AA+AV
(n= 383)
VV
(n= 176)
Count % Count % p
After 2 years
Death 21 5.5 12 6.8 0.548
AMI 22 5.7 16 9.1 0.138
Death + AMI 39 10.2 26 14.8 0.113
Revascularization Intervention 28 7.3 21 11.9 0.073
Events 84 21.9 49 27.8 0.098
Dysglycemic patients
AA+AV
(n= 180)
VV
(n= 80)
Count % Count % p
After 2 years
Death 13 7.2 8 10.0 0.514
AMI 7 3.9 9 11.3 0.023
Death + AMI 18 10.0 16 20.0 0.032
Revascularization intervention 11 6.1 13 16.3 0.006
Events 36 20.0 26 32.5 0.020
Normoglycemic patients
AA+AV
(n= 203)
VV
(n= 96)
Count % Count % p
After 2 years
Death 8 3.9 4 4.2 0.765
AMI 15 7.4 7 7.3 0.904
Death + AMI 21 10.3 10 10.4 0.883
Revascularization Intervention 17 8.4 8 8.3 0.969
Events 48 23.6 23 24.0 0.831
AMI: acute myocardial infarction.
Death CV: cardiovascular death.
PCI: percutaneous coronary intervention.
p-values are for log-rank statistics of KM curve comparison of 2 year
follow-up period.
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In our study, dysglycemic patients presented higher
incidence of AMI, necessity of a new revascularization
intervention and combined events, despite mortality
being the same. Actually, it was described that functional
alterations in UCP2 leads to a higher production of ROS
that is already increased in dysglycemic patients and can
worsen the macrovascular disease and the atheroscle-
rotic process [3].
A study described that, in humans, the extent of
uncoupling is partially regulated by the genetic poly-
morphism Ala55Val, in which the VV genotype uncouples
at a lower rate than the AA genotype [20]. Other studies
reported that the A allele was associated with the presence
of higher oxidative stress markers and showed synergistic
effect with other risk factors (obesity, hypertension and
diabetes) [21,22].
There are some limitations in our study. First, we were
not able to perform replication studies in a similar sam-
ple because there are very few studies similar to MASSII
in the literature. Second, our sample size only provide
80% power to detect an association with death, AMI,
revascularization intervention, events variables with an
effect size of 1.7–2.4 or 1.8–3.6 for the A55V polymor-
phism in the total group and in the dysglycemic patients,
respectively. We recognize that such effects are highly
unlikely for common genetic variants and reaffirm the
need for the development of increased samples of
multivessel CAD patients with long-term follow-up
period for the identification of more modest effects.
Third, it is not possible to completely exclude the inter-
action between the use of concomitant drugs, other
genetic markers, ethnicity and other covariates on our
findings. We only analyzed the A55V polymorphism
despite of others polymorphisms in the UCP2 gene have
already been identified and some of them are in linkage
disequilibrium with A55V. For example, A866>G has
already been associated to increased cardiovascular
events risk, cardiometabolic disease and it represents a
novel candidate gene for beta-blocker response, particu-
larly among patients with diabetes [23].
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Figure 1 Survival curves of dysglycemic patients genotyped for the polymorphism A55V.
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A recent meta-analysis has showed that the UCP2 -
866G/A polymorphism is unlikely associated with
increased type 2 diabetes risk in the Asian and European
descent. In contrast, further results indicate that the
UCP2 Ala55Val and UCP3 -55C/T polymorphisms may
indeed be risk factors for susceptibility to type 2 diabetes
in individuals of Asian descent, but not in individuals of
European descent [24].
After 2 years of follow-up, dysglycemic patients carrying
the VV genotype had higher incidence of AMI, death
+AMI, new revascularization intervention and combined
events compared to patients carrying other genotypes.
After 5 years of follow-up, we were not able in detect
these differences according to genotypic groups, except
for AMI incidence. We speculate that the predictive effect
of UCP2 genotype in dysglycemic patients could be
related to the time of illness. On the other hand, there is
no experimental evidence suggesting that the duration of
diabetes could play a role in this result. Further studies are
necessary to establish the role of VV genotype as an inde-
pendent genetic marker of cardiovascular events in this
specific subgroup.
Conclusion
Taken together, our findings corroborate the hypothesis
that A55V polymorphism is associated with UCP2 func-
tional alterations that may increase the risk of cardiovascu-
lar events in patients with previous CAD and dysglycemia.
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